Department of Hematology and Central Hematological Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
IDSC-Insel Data Science Centre, 3010 Bern, Switzerland.
Medicina (Kaunas). 2024 Sep 26;60(10):1576. doi: 10.3390/medicina60101576.
: In clinical practice, neutropenia is frequently accompanied by other cytopenia; isolated non-chemotherapy-induced severe neutropenia is less frequent and its differential diagnosis can be challenging. In this real-world study with data collected over a 5-year period in a tertiary referral hospital, we primarily sought to identify underlying causes of isolated severe neutropenia (<0.5 × 10/L). Secondly, we aimed to analyze its management and outcomes. : From 444,926 screened patients, after exclusion of patients with chemotherapy, radiotherapy, hematological neoplasms, additional cytopenia, and benign ethnic neutropenia, we identified and analyzed data from 70 patients (0.015%) with isolated severe neutropenia. We thus confirmed that the occurrence of isolated severe neutropenia is a rare event, even in a tertiary hospital. : The median age at diagnosis was 34 years (range 1-81) and 65% were female. Acute neutropenia was more frequently observed (n = 46/70, 65.7%); the main underlying causes in this group were drugs (n = 36/46, 78%) followed by infections (n = 10/46, 21.7%). We identified 24 (34.3%) patients with chronic neutropenia. The majority of them (n = 12/24, 50%) had an idiopathic form (CIN), 8/24 (33%) were autoimmune (AIN), and 4/24 (17%) were congenital. : This study demonstrates the rarity and heterogeneity of isolated severe neutropenia and the steps to consider in its diagnostic work-up and management. Epidemiological characteristics, diagnostic work-up, and management including hospitalizations are described. Due to the high frequency of metamizole-induced neutropenia observed in this study, we want to raise awareness about its use, since this complication generates frequent hospitalizations even in young, otherwise healthy patients. Furthermore, recurrent infections in chronic forms of idiopathic neutropenia were quite common, suggesting a difference in phenotypes and need for therapy consideration depending on the clinical course.
在临床实践中,中性粒细胞减少症常伴有其他细胞减少症;孤立性非化疗引起的严重中性粒细胞减少症较少见,其鉴别诊断具有挑战性。在这项为期 5 年在三级转诊医院收集数据的真实世界研究中,我们主要旨在确定孤立性严重中性粒细胞减少症(<0.5×10/L)的潜在原因。其次,我们旨在分析其管理和结果。
从 444926 名筛选患者中,排除接受化疗、放疗、血液系统恶性肿瘤、其他细胞减少症和良性种族中性粒细胞减少症的患者后,我们确定并分析了 70 名孤立性严重中性粒细胞减少症患者的数据(0.015%)。因此,我们证实即使在三级医院,孤立性严重中性粒细胞减少症的发生也是一种罕见事件。
诊断时的中位年龄为 34 岁(范围 1-81 岁),65%为女性。更常观察到急性中性粒细胞减少症(n=46/70,65.7%);该组的主要潜在原因是药物(n=36/46,78%),其次是感染(n=10/46,21.7%)。我们发现 24 名(34.3%)慢性中性粒细胞减少症患者。其中大多数(n=12/24,50%)为特发性(CIN),8/24(33%)为自身免疫性(AIN),4/24(17%)为先天性。
这项研究表明,孤立性严重中性粒细胞减少症的罕见性和异质性,以及在其诊断性工作流程和管理中应考虑的步骤。描述了流行病学特征、诊断性工作流程和包括住院在内的管理。由于在这项研究中观察到甲氨蝶呤引起的中性粒细胞减少症的频率很高,我们想提高对其使用的认识,因为即使在年轻、健康的患者中,这种并发症也会导致频繁住院。此外,慢性特发性中性粒细胞减少症的复发性感染相当常见,表明表型不同,需要根据临床病程考虑治疗。